Identification of a pan-orthoebolavirus-reactive antibody from an rVSV-EBOV vaccinated individual
- 1Faculty of Medicine and University Hospital Cologne, University of Cologne
Abstract
Orthoebolaviruses such as Ebola virus (EBOV), Sudan virus (SUDV) and Bundibugyo virus (BDBV) can cause severe disease with high case-fatality rates. While licensed EBOV vaccines and therapeutic antibodies protect against EBOV infection, no single monoclonal antibody currently provides broad protection across multiple orthoebolaviruses. Here, we analyzed the humoral immune response of an rVSV-EBOV vaccinee to identify pan-orthoebolavirus-neutralizing antibodies. Using BDBV- and SUDV-glycoproteins for single B cell-sorting, we identified B10, which neutralized authentic EBOV and SUDV, with potent activity against SUDV compared with established cross-reactive antibodies. Structural analysis mapped antibody B10 binding to the pan-orthoebolavirus conserved GP2-stalk/HR2 region, associated with asymmetric trimer destabilization and spike opening. In vivo, B10 showed significant prophylactic efficacy in an EBOV mouse model and partial protection with antiviral activity in a SUDV mouse model. Together, these findings demonstrate that rVSV-EBOV vaccination induced the development of a broadly orthoebolavirus-neutralizing antibody that holds exeptional therapeutic potential.
Related
- Eastern equine encephalitis virus-vaccinated mice are protected against Madariaga virus despite negligible neutralizing antibody titers
- Epistasis and pleiotropy constrain the evolution of cross-reactive breadth in a broadly neutralizing influenza antibody
- Identification of Cysteine-Reactive Early Mitotic Inhibitors
- From video to encounter histories: individual identification and machine vision for salmonid capture-recapture monitoring
- Identification and characterization of a human antibody profile inversely associated with adverse cardiovascular events
BibTeX
@misc{tarnow2026identification,
title = {{Identification of a pan-orthoebolavirus-reactive antibody from an rVSV-EBOV vaccinated individual}},
author = {P. Tarnow and H. Cohen-Dvashi and C. Rohde and V. Kraehling and L. Ullrich and L. Gieselmann and H. Zar Shuker and S. Amatya and A. Fathi and A. Kupke and C. Kreer and BSL-4 Animal Facility Team and M. Koch and M. M. Addo and S. Becker and R. Diskin and M. Zehner and F. Klein},
howpublished = {bioRxiv},
year = {2026},
month = aug,
doi = {10.64898/2026.08.28.747769},
url = {https://www.biorxiv.org/content/10.64898/2026.08.28.747769v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Identification of a pan-orthoebolavirus-reactive antibody from an rVSV-EBOV vaccinated individual
AU - P. Tarnow
AU - H. Cohen-Dvashi
AU - C. Rohde
AU - V. Kraehling
AU - L. Ullrich
AU - L. Gieselmann
AU - H. Zar Shuker
AU - S. Amatya
AU - A. Fathi
AU - A. Kupke
AU - C. Kreer
AU - BSL-4 Animal Facility Team
AU - M. Koch
AU - M. M. Addo
AU - S. Becker
AU - R. Diskin
AU - M. Zehner
AU - F. Klein
PY - 2026
DA - 2026/08/28
PB - bioRxiv
DO - 10.64898/2026.08.28.747769
UR - https://www.biorxiv.org/content/10.64898/2026.08.28.747769v1
AB - Orthoebolaviruses such as Ebola virus (EBOV), Sudan virus (SUDV) and Bundibugyo virus (BDBV) can cause severe disease with high case-fatality rates. While licensed EBOV vaccines and therapeutic antibodies protect against EBOV infection, no single monoclonal antibody currently provides broad protection across multiple orthoebolaviruses. Here, we analyzed the humoral immune response of an rVSV-EBOV vaccinee to identify pan-orthoebolavirus-neutralizing antibodies. Using BDBV- and SUDV-glycoproteins for single B cell-sorting, we identified B10, which neutralized authentic EBOV and SUDV, with potent activity against SUDV compared with established cross-reactive antibodies. Structural analysis mapped antibody B10 binding to the pan-orthoebolavirus conserved GP2-stalk/HR2 region, associated with asymmetric trimer destabilization and spike opening. In vivo, B10 showed significant prophylactic efficacy in an EBOV mouse model and partial protection with antiviral activity in a SUDV mouse model. Together, these findings demonstrate that rVSV-EBOV vaccination induced the development of a broadly orthoebolavirus-neutralizing antibody that holds exeptional therapeutic potential.
ER -